MarketPulse

SG&A expenses

2 articles
The Motley FoolThe Motley Fool··Rich Smith

Lenz Therapeutics Stock Crashes 11.2% on Missed Earnings and Weak VIZZ Launch

Lenz Therapeutics stock plummeted 11.2% after Q4 earnings miss, larger-than-expected losses, and disappointing VIZZ prescription uptake despite strong pipeline projections.
LENZstock declineearnings miss
BenzingaBenzinga··Erica Kollmann

Ulta Beauty Beats Earnings But Slides 8.6% on Cost Concerns

Ulta Beauty beat Q4 earnings expectations with $8.01 EPS and $3.898B revenue, yet stock fell 8.63% due to surging operating expenses.
ULTAstock declineguidance